Our results could facilitate the rational design of therapeutic strategies targeting tumors with dysregulated PI3K/AKT signaling, and may suggest that mTOR-specific inhibitors could potentially be developed to prevent cellular senescence, ameliorate aging, and treat diabetes, neurodegeneration, and muscle disease. Here, AKT1 is linked to diabetes mellitus.